コンテンツへスキップ
Merck
  • 3D bioprinting via an in situ crosslinking technique towards engineering cartilage tissue.

3D bioprinting via an in situ crosslinking technique towards engineering cartilage tissue.

Scientific reports (2019-12-29)
Jonathan H Galarraga, Mi Y Kwon, Jason A Burdick
要旨

3D bioprinting is a promising approach for the repair of cartilage tissue after damage due to injury or disease; however, the design of 3D printed scaffolds has been limited by the availability of bioinks with requisite printability, cytocompatibility, and bioactivity. To address this, we developed an approach termed in situ crosslinking that permits the printing of non-viscous, photocrosslinkable bioinks via the direct-curing of the bioink with light through a photopermeable capillary prior to deposition. Using a norbornene-modified hyaluronic acid (NorHA) macromer as a representative bioink and our understanding of thiol-ene curing kinetics with visible light, we varied the printing parameters (e.g., capillary length, flow rate, light intensity) to identify printing conditions that were optimal for the ink. The printing process was cytocompatible, with high cell viability and homogenous distribution of mesenchymal stromal cells (MSCs) observed throughout printed constructs. Over 56 days of culture in chondrogenic media, printed constructs increased in compressive moduli, biochemical content (i.e., sulfated glycosaminoglycans, collagen), and histological staining of matrix associated with cartilage tissue. This generalizable printing approach may be used towards the repair of focal defects in articular cartilage or broadly towards widespread biomedical applications across a range of photocrosslinkable bioinks that can now be printed.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
フェニル-2,4,6-トリメチルベンゾイルホスフィン酸リチウム, ≥95%
Sigma-Aldrich
エチジウムホモダイマー, suitable for fluorescence, ~90% (HPCE)